Published in Pharmacol Ther on February 01, 2007
Select cognitive deficits in vasoactive intestinal peptide deficient mice. BMC Neurosci (2008) 1.06
Ethanol inhibits neuronal differentiation by disrupting activity-dependent neuroprotective protein signaling. Proc Natl Acad Sci U S A (2008) 0.95
Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res (2011) 0.89
HP1 recruits activity-dependent neuroprotective protein to H3K9me3 marked pericentromeric heterochromatin for silencing of major satellite repeats. PLoS One (2011) 0.89
Potential drugs and methods for preventing or delaying the progression of Huntington's disease. Recent Pat CNS Drug Discov (2011) 0.89
Expression of activity-dependent neuroprotective protein in the immune system: possible functions and relevance to multiple sclerosis. Neuroimmunomodulation (2009) 0.86
NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42). BMC Neurosci (2008) 0.86
The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease. Proteomes (2016) 0.85
Novel marker for the onset of frontotemporal dementia: early increase in activity-dependent neuroprotective protein (ADNP) in the face of Tau mutation. PLoS One (2014) 0.85
Effects of ethanol and NAP on cerebellar expression of the neural cell adhesion molecule L1. PLoS One (2011) 0.82
NAP protects against cyanide-related microtubule destruction. J Neural Transm (Vienna) (2009) 0.80
Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. EPMA J (2010) 0.80
Strategies to defeat ketamine-induced neonatal brain injury. Neuroscience (2012) 0.78
Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP). Front Endocrinol (Lausanne) (2012) 0.75
Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease. CNS Neurol Disord Drug Targets (2014) 0.75
Impairment of mitochondria dynamics by human A53T α-synuclein and rescue by NAP (davunetide) in a cell model for Parkinson's disease. Exp Brain Res (2016) 0.75